科拓生物(300858) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥80,716,575.97, representing a 35.97% increase compared to ¥59,362,530.32 in the same period last year[7]. - Net profit attributable to shareholders was ¥21,558,322.68, up 43.07% from ¥15,068,263.54 year-on-year[7]. - Basic and diluted earnings per share increased by 8.33% to ¥0.26 from ¥0.24 in the same period last year[7]. - Total operating revenue for Q1 2021 reached CNY 80,716,575.97, compared to CNY 59,362,530.32 in the previous period, indicating a significant increase[44]. - The net profit for the first quarter reached CNY 21,558,322.68, compared to CNY 15,068,263.54 in the same period last year, representing a growth of approximately 43.3%[46]. - The operating profit for the first quarter was CNY 25,935,302.59, compared to CNY 20,359,440.53 in the previous year, reflecting a growth of approximately 27.5%[46]. - The total profit for the first quarter was CNY 25,835,238.25, compared to CNY 18,102,505.30 in the previous year, representing an increase of approximately 42.5%[46]. Cash Flow - The net cash flow from operating activities was ¥19,110,813.82, a significant improvement from a negative cash flow of ¥1,481,423.99 in the previous year, marking a 1,390.03% increase[7]. - Cash flow from operating activities was CNY 19,110,813.82, a significant increase of 1390.03% compared to a negative cash flow of CNY -1,481,423.99 in the same period last year[20]. - The cash flow from operating activities for Q1 2021 was ¥122,267,392.49, compared to ¥60,254,713.07 in the previous period, indicating a substantial increase[53]. - The cash inflow from the recovery of investments for the parent company was ¥385,324,608.59, a substantial increase from ¥26,050,060.28 in the same period last year[58]. - The company reported a total operating cash inflow of ¥125,004,472.30, which is an increase of approximately 97% from ¥63,258,584.97 in the previous year[54]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,016,465,616.03, a 1.72% increase from ¥999,245,812.07 at the end of the previous year[7]. - The total assets as of March 31, 2021, amounted to CNY 1,016,465,616.03, up from CNY 999,245,812.07 at the end of 2020[39]. - The total liabilities decreased to CNY 61,412,684.47 from CNY 66,658,603.19, showing a decline of approximately 8.5%[38]. - The company’s total liabilities increased from ¥66,658,603.19 to ¥71,479,794.01, reflecting a rise of approximately 7%[62]. - The total current assets were CNY 765,757,693.48, with cash and cash equivalents at CNY 171,936,567.89[64]. Shareholder Information - The company reported a total of 10,006 common shareholders at the end of the reporting period[11]. - The top shareholder, Sun Tiansong, holds 30.24% of the shares, totaling 24,954,801 shares[11]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12]. Research and Development - Research and development expenses rose by 86.36% to CNY 6,362,429.11, driven by increased R&D activities[18]. - Research and development expenses amounted to CNY 6,362,429.11, up from CNY 3,414,045.63, indicating a year-over-year increase of about 86.5%[46]. Government Support - The company received government subsidies amounting to ¥1,208,098.97 during the reporting period[8]. Other Financial Metrics - The total amount of raised funds is CNY 436.18 million, with CNY 2.25 million invested in the current quarter[27]. - The project for producing 30 tons of lactic acid bacteria powder and other products has achieved a completion rate of 100.02%[27]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[30]. - There were no violations of external guarantees during the reporting period[29].